glycopeptide alpha-N-acetylgalactosaminidase

hydrolyzes terminal D-galactosyl-N-acetyl-alpha-D-galactosaminide residues from glycopeptides & glycoproteins linked by serine or threonine residues

Also Known As:

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Abed, Jawad: 1 article (08/2016)
2.	Almogy, Gideon: 1 article (08/2016)
3.	Atlan, Karine A: 1 article (08/2016)
4.	Bachrach, Gilad: 1 article (08/2016)
5.	Brennan, Caitlin A: 1 article (08/2016)
6.	Chaushu, Stella: 1 article (08/2016)
7.	Earl, Ashlee M: 1 article (08/2016)
8.	Emgård, Johanna E M: 1 article (08/2016)
9.	Faroja, Mouhammad: 1 article (08/2016)
10.	Garrett, Wendy S: 1 article (08/2016)

Related Diseases

1.	Adenocarcinoma 08/10/2016 - "F. nucleatum binding to clinical adenocarcinomas correlates with Gal-GalNAc expression and is reduced upon O-glycanase treatment. " 02/01/1995 - "O-Glycanase treatment released increased amounts of TF antigen from both colonic adenocarcinoma (8.0 +/- 3.9 ng/micrograms protein, n = 11; P < 0.0001 ANOVA) and ulcerative colitis mucin (3.3 +/- 0.3 ng/micrograms protein, n = 5; P = 0.04) compared with mucin samples from histologically normal mucosa distant from carcinoma (1.5 +/- 1.1 ng/micrograms protein, n = 9). " 02/01/1995 - "Samples of adenocarcinoma, inflammatory bowel disease (ulcerative colitis), and normal mucin were treated with O-glycanase, the liberated disaccharide was separated from the glycoprotein and analyzed using dual CarboPac PA-100 column high performance anion-exchange chromatography coupled with pulsed amperometric detection. "
2.	Activated Protein C Resistance (APC Resistance) 06/15/1997 - "O-glycanase treatment of factor V did not change the APC resistance ratio. "
3.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 02/01/1995 - "Samples of adenocarcinoma, inflammatory bowel disease (ulcerative colitis), and normal mucin were treated with O-glycanase, the liberated disaccharide was separated from the glycoprotein and analyzed using dual CarboPac PA-100 column high performance anion-exchange chromatography coupled with pulsed amperometric detection. "
4.	Hepatocellular Carcinoma (Hepatoma) 03/22/1996 - "Transduction of cultured Hepa (mouse hepatoma) cells and LDLR-deficient CHO-ldlA7 cells in vitro by the virus led to high-level expression of immunoreactive VLDLR proteins with molecular sizes of 143 kDa and 161 kDa. Digestion of the cell extract with the enzymes neuraminidase, N-glycanase, and O-glycanase resulted in the stepwise lowering of the apparent size of the 161-kDa species toward the 143-kDa species. "
5.	Acute Erythroblastic Leukemia (Erythroleukemia) 10/05/1987 - "A monoclonal antibody (mAb-233) directed against an epitope in the nonglycosylated carboxyl-terminal region of human erythrocyte glycophorin A (GPA) was used in combination with metabolic labeling, the modification of N- and O-linked oligosaccharide processing by tunicamycin and monensin, and digestions with neuraminidase and O-glycanase to elucidate the pathway of GPA biogenesis in K562 human erythroleukemia cells. "

Related Drugs and Biologics

1.	Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase
2.	Tunicamycin
3.	Proteins (Proteins, Gene)
4.	Neuraminidase (Sialidase)
5.	Epitopes
6.	Thomsen-Friedenreich antigen
7.	Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase
8.	Polysaccharides (Glycans)
9.	Oligosaccharides
10.	Mucins